NO20053860L - COP 1 for behandling av inflammatorisk tarmsykdom. - Google Patents

COP 1 for behandling av inflammatorisk tarmsykdom.

Info

Publication number
NO20053860L
NO20053860L NO20053860A NO20053860A NO20053860L NO 20053860 L NO20053860 L NO 20053860L NO 20053860 A NO20053860 A NO 20053860A NO 20053860 A NO20053860 A NO 20053860A NO 20053860 L NO20053860 L NO 20053860L
Authority
NO
Norway
Prior art keywords
treatment
cop
inflammatory bowel
bowel disease
copolymer
Prior art date
Application number
NO20053860A
Other languages
English (en)
Other versions
NO333579B1 (no
NO20053860D0 (no
Inventor
Rina Ahoroni
Ruth Amon
Basak Kayhan
Ruth Arnon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20053860D0 publication Critical patent/NO20053860D0/no
Publication of NO20053860L publication Critical patent/NO20053860L/no
Publication of NO333579B1 publication Critical patent/NO333579B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører anvendelsen av Kopolymer I (glatiramer acetat), et Kopolymer I -relatert polypeptid, eller et Kopolymer I -relatert peptid, for behandling av inflammatoriske tannsykdommer, slik som Crohns sykdom og ulcerativ kolitt.
NO20053860A 2003-01-21 2005-08-18 Anvendelse av kopolymer 1 for fremstilling av en farmasoytisk sammensetning for behandling av inflammatoriske tarmsykdommer. NO333579B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44113603P 2003-01-21 2003-01-21
PCT/IL2004/000054 WO2004064717A2 (en) 2003-01-21 2004-01-20 Cop 1 for treatment of inflammatory bowel diseases

Publications (3)

Publication Number Publication Date
NO20053860D0 NO20053860D0 (no) 2005-08-18
NO20053860L true NO20053860L (no) 2005-10-20
NO333579B1 NO333579B1 (no) 2013-07-15

Family

ID=32771907

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053860A NO333579B1 (no) 2003-01-21 2005-08-18 Anvendelse av kopolymer 1 for fremstilling av en farmasoytisk sammensetning for behandling av inflammatoriske tarmsykdommer.

Country Status (14)

Country Link
US (1) US8008258B2 (no)
EP (1) EP1592384B1 (no)
AU (1) AU2004206120B2 (no)
CA (1) CA2513567C (no)
DK (1) DK1592384T3 (no)
ES (1) ES2397836T3 (no)
MX (1) MXPA05007711A (no)
NO (1) NO333579B1 (no)
NZ (1) NZ569331A (no)
PT (1) PT1592384E (no)
RU (1) RU2339397C2 (no)
SI (1) SI1592384T1 (no)
WO (1) WO2004064717A2 (no)
ZA (1) ZA200505733B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US7429374B2 (en) * 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
BRPI0510738A (pt) * 2004-05-07 2007-11-20 Peptimmune Inc métodos de tratar doenças com copolìmeros aleatórios
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
WO2006083608A1 (en) * 2005-02-02 2006-08-10 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
JP2011529078A (ja) * 2008-07-25 2011-12-01 ザ・ジョンズ・ホプキンス・ユニバーシティー 自己免疫疾患を治療および予防するための方法および組成物
KR20170123354A (ko) 2009-08-20 2017-11-07 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 글라티라머 아세테이트를 포함하는 약제
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2645509T3 (es) 2010-07-26 2017-12-05 Qu Biologics Inc Composiciones antiinflamatorias inmunogénicas
JP2013541010A (ja) 2010-10-11 2013-11-07 テバ ファーマシューティカル インダストリーズ リミティド グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
RU2020120075A (ru) 2014-05-02 2020-07-03 Кью Байолоджикс Инк. Противомикробная иммуномодуляция
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US20210220428A1 (en) 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2018211498A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
EP3624815A4 (en) 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en) * 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
EP1105414A2 (en) 1998-07-23 2001-06-13 President And Fellows of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2327301T3 (es) 1998-09-25 2009-10-27 Yeda Research And Development Co., Ltd. Polipeptidos relacionados con el copolimero 1 para su uso como marcadores de pesos moleculares y para uso terapeutico.
AU6281599A (en) * 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
EP1128839A4 (en) * 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
CA2396871A1 (en) * 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
DE60120648D1 (de) 2000-02-18 2006-07-27 Yeda Res & Dev Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
AU2003204344A1 (en) * 2002-05-23 2003-12-11 Milder, Dan George Compositions and methods for the treatment of autoimmune diseases and neurological disorders
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe

Also Published As

Publication number Publication date
EP1592384A2 (en) 2005-11-09
CA2513567A1 (en) 2004-08-05
AU2004206120A1 (en) 2004-08-05
EP1592384B1 (en) 2012-10-31
MXPA05007711A (es) 2005-09-30
NO333579B1 (no) 2013-07-15
CA2513567C (en) 2012-10-23
SI1592384T1 (sl) 2013-03-29
RU2005126412A (ru) 2006-01-27
ZA200505733B (en) 2006-10-25
NO20053860D0 (no) 2005-08-18
RU2339397C2 (ru) 2008-11-27
AU2004206120B2 (en) 2009-09-24
US20060264354A1 (en) 2006-11-23
NZ569331A (en) 2010-08-27
PT1592384E (pt) 2013-01-28
DK1592384T3 (da) 2012-12-17
EP1592384A4 (en) 2008-12-31
WO2004064717A2 (en) 2004-08-05
ES2397836T3 (es) 2013-03-11
US8008258B2 (en) 2011-08-30
WO2004064717A3 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
NO20053860L (no) COP 1 for behandling av inflammatorisk tarmsykdom.
CA2478621A1 (en) Botulinum toxin pharmaceutical compositions
TWI455721B (zh) 癌疫苗組合物
HK1154211A1 (zh) 預防和減少失血和炎症反應
HUP0301452A2 (hu) Fotokemoterápiás szert és mukoadhéziós szert tartalmazó gyógyszerkészítmény és alkalmazása
HRP20041152B1 (en) Pharmaceutical formulations
DK1210430T3 (da) MUC-1-afledte peptider
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
NO20055692L (no) Intravenos injeksjon av ikkeneurotoksiske plasminogenaktivatorer til behandling av cerebralt slag
NO972849D0 (no) Peptid p277 analoger og farmasöytiske sammensetninger som omfatter disse for behandling eller diagnostikk av diabetes
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
DK1429800T3 (da) Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose
MXPA03010684A (es) Peptidos y el uso de los mismos para oscurecer la piel.
MXPA02000465A (es) Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6.
HUP0303167A2 (hu) IB-alfa vérlemezke glikoproteinnel képzett fúziós polipeptidek, továbbá eljárások alkalmazásukra
DE69630583D1 (de) Peptide, bronchodilator und den blutstrom verbesserndes mittel
HUP0401593A2 (hu) A PTX3 hosszú pentraxin alkalmazása gyógyhatású készítmény előállítására autoimmun betegségek megelőzésére és kezelésére
DE50113010D1 (de) Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
JP2004513615A5 (no)
NO20052525D0 (no) Spleisevariant av humant hypofyseveksthormon
HUP0102853A1 (hu) Moraxella catarrhalis-ból származó vegyületek
HUP0200162A2 (hu) Haemophilus somnus transzferrin-kötő fehérjék klónozása és expresszálása
CY1113827T1 (el) Cop 1 για την αγωγη των φλεγμονωδων παθησεων του εντερου
PT789761E (pt) Scf humano, uma respectiva variante de processamento, sua utilizacao farmaceutica

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees